Placebo responders with moderate-to-severe hidradenitis suppurativa experience declines in inflammation as measured by C-reactive protein: a post hoc analysis of two double-blinded, randomized-controlled trials
Saved in:
| Main Authors: | Simon J. Gunter, MPhil, Martina L. Porter, MD, Alexa B. Kimball, MD, MPH |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2024-10-01
|
| Series: | International Journal of Women's Dermatology |
| Online Access: | http://journals.lww.com/10.1097/JW9.0000000000000171 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hidradenitis suppurativa electronic medical record (EPIC) tool: A convenient Tool for hidradenitis suppurativa specialty clinics
by: Zachary Wendland, MD, MPH, et al.
Published: (2025-04-01) -
Mucopolysaccharidosis type IVA and severe hidradenitis suppurativa: A case series
by: Jorga Fialová, MD, et al.
Published: (2025-08-01) -
Surgical Approach to Hidradenitis Suppurativa
by: L. Mateu-Arrom, et al.
Published: (2025-06-01) -
Hidradenitis suppurativa and daily lifestyle
by: Natsuko Saito-Sasaki, et al.
Published: (2025-06-01) -
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials
by: John R. Ingram, et al.
Published: (2025-05-01)